Physician profile
Saurabh Chawla
NPI 1528137411
$7,918.41
in general payments reported to CMS, 2019-2025
33 companies · $1,829 in 2025
The $1,829 reported for 2025 was more than what 88% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $87.87 · 2021: $843 · 2022: $972 · 2023: $1,231 · 2024: $2,694 · 2025: $1,829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,123 · Travel and Lodging: $564 · Education: $66.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,122.76 |
| Travel and Lodging | $564.02 |
| Education | $66.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $775.01 | 2021-2025 | Farxiga, Lokelma |
| Opko Pharmaceuticals, LLC | $696.85 | 2019-2025 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $678.24 | 2019-2025 | Jynarque, Voyxact |
| Fresenius USA Marketing, INC. | $597.80 | 2020-2025 | Velphoro, Korsuva, Velphoro |
| Travere Therapeutics, INC. | $581.03 | 2022-2025 | Filspari |
| Ovesco Endoscopy USA, INC. | $564.02 | 2024 | |
| Amgen INC. | $492.46 | 2021-2025 | Tavneos, Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $463.22 | 2021-2025 | |
| Ardelyx, INC. | $423.97 | 2024-2025 | Ibsrela, Xphozah 30 Mg |
| Vifor Pharma, INC. | $362.42 | 2019-2024 | Veltassa |
| Alexion Pharmaceuticals, INC. | $266.56 | 2019-2025 | Ultomiris |
| Cook Medical LLC | $255.18 | 2019-2025 | Hemospray |
| Mallinckrodt Hospital Products INC. | $224.09 | 2021-2022 | |
| Calliditas Therapeutics US INC. | $205.80 | 2022-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $159.93 | 2020-2024 | Benlysta |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $149.48 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $128.92 | 2021-2025 | |
| Ani Pharmaceuticals, INC. | $128.50 | 2023-2024 | Purified Cortrophin Gel |
| Inari Medical, INC. | $122.16 | 2021 | |
| Azurity Pharmaceuticals, INC. | $103.67 | 2023 | Edarbi |
| Aurinia Pharma U.S., INC. | $99.61 | 2022-2024 | Lupkynis |
| Lilly USA, LLC | $77.10 | 2024-2025 | Jardiance |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $64.72 | 2023-2024 | |
| Novo Nordisk INC | $60.75 | 2024-2025 | Ozempic |
| Akebia Therapeutics INC | $53.94 | 2025 | Vafseo |
| Takeda Pharmaceuticals U.S.A., INC. | $29.75 | 2025 | Gattex |
| Scpharmaceuticals INC. | $28.96 | 2024 | |
| Cormedix INC. | $27.27 | 2025 | Defencath |
| Alnylam Pharmaceuticals INC. | $26.42 | 2021 | |
| Chiesi USA, INC. | $19.48 | 2025 | Kengreal, Cleviprex |
| Genentech USA, INC. | $19.43 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.07 | 2022 | |
| Shield Therapeutics INC | $13.60 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saurabh Chawla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.